Edward R. Scheffer Cliff

1.2k total citations · 2 hit papers
59 papers, 576 citations indexed

About

Edward R. Scheffer Cliff is a scholar working on Oncology, Hematology and Economics and Econometrics. According to data from OpenAlex, Edward R. Scheffer Cliff has authored 59 papers receiving a total of 576 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 16 papers in Hematology and 14 papers in Economics and Econometrics. Recurrent topics in Edward R. Scheffer Cliff's work include Multiple Myeloma Research and Treatments (16 papers), Health Systems, Economic Evaluations, Quality of Life (12 papers) and CAR-T cell therapy research (11 papers). Edward R. Scheffer Cliff is often cited by papers focused on Multiple Myeloma Research and Treatments (16 papers), Health Systems, Economic Evaluations, Quality of Life (12 papers) and CAR-T cell therapy research (11 papers). Edward R. Scheffer Cliff collaborates with scholars based in United States, Australia and Canada. Edward R. Scheffer Cliff's co-authors include Aaron S. Kesselheim, Ghulam Rehman Mohyuddin, David A. Russler‐Germain, David M. Cordas dos Santos, Roni Shouval, Miguel‐Angel Perales, Kai Rejeski, Amar H. Kelkar, William B. Feldman and Adam Raymakers and has published in prestigious journals such as New England Journal of Medicine, JAMA and Nature Medicine.

In The Last Decade

Edward R. Scheffer Cliff

53 papers receiving 569 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy

2024 99 citations David M. Cordas dos Santos, Roni Shouval et al. profile →
Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients

2024 44 citations Roni Shouval, Edward R. Scheffer Cliff et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Edward R. Scheffer Cliff United States	12	335	140	110	99	78	59	576
Arushi Khurana United States	13	250 0.7×	111 0.8×	182 1.7×	59 0.6×	71 0.9×	79	491
Jacob Garcia United States	18	867 2.6×	145 1.0×	203 1.8×	60 0.6×	72 0.9×	47	1.0k
Iris Isufi United States	12	283 0.8×	96 0.7×	159 1.4×	127 1.3×	121 1.6×	61	535
Eri Matsuki Japan	11	249 0.7×	61 0.4×	134 1.2×	153 1.5×	127 1.6×	41	492
Ewa Kalinka‐Warzocha Poland	18	504 1.5×	160 1.1×	117 1.1×	32 0.3×	92 1.2×	91	944
Al‐Ola Abdallah United States	14	550 1.6×	414 3.0×	60 0.5×	534 5.4×	97 1.2×	134	871
Tadahiko Igarashi Japan	14	296 0.9×	131 0.9×	107 1.0×	143 1.4×	127 1.6×	45	577
Danai Dima United States	12	233 0.7×	170 1.2×	56 0.5×	180 1.8×	40 0.5×	69	409
Larysa Sanchez United States	12	335 1.0×	253 1.8×	39 0.4×	376 3.8×	61 0.8×	65	606
Lu Yu China	16	383 1.1×	158 1.1×	38 0.3×	131 1.3×	90 1.2×	48	685

Countries citing papers authored by Edward R. Scheffer Cliff

Since Specialization

Citations

This map shows the geographic impact of Edward R. Scheffer Cliff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward R. Scheffer Cliff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward R. Scheffer Cliff more than expected).

Fields of papers citing papers by Edward R. Scheffer Cliff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward R. Scheffer Cliff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward R. Scheffer Cliff. The network helps show where Edward R. Scheffer Cliff may publish in the future.

Co-authorship network of co-authors of Edward R. Scheffer Cliff

This figure shows the co-authorship network connecting the top 25 collaborators of Edward R. Scheffer Cliff. A scholar is included among the top collaborators of Edward R. Scheffer Cliff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward R. Scheffer Cliff. Edward R. Scheffer Cliff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cliff, Edward R. Scheffer, Thomas E. Lew, Florian Simon, et al.. (2025). Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial. Journal of Clinical Oncology. 44(3). 254–256.

Kim, John, Aaron S. Kesselheim, Edward R. Scheffer Cliff, & Benjamin N. Rome. (2025). Medicare spending and use of subcutaneous biologic formulations with hyaluronidase. The Oncologist. 30(6).

Reynolds, Gemma, et al.. (2025). Regulatory and Clinical Outcomes of Nononcology Accelerated Approvals. JAMA. 334(13). 1194–1194. 1 indexed citations

Tibau, Ariadna, et al.. (2025). Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study. EClinicalMedicine. 84. 103088–103088. 1 indexed citations

Shouval, Roni, et al.. (2024). Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients. Clinical Cancer Research. 30(20). 4690–4700. 44 indexed citations breakdown →

Rudà, Roberta, et al.. (2024). Financial challenges of being on long-term, high-cost medications. Neuro-Oncology Practice. 12(Supplement_1). i49–i58. 4 indexed citations

Shah, Veer, et al.. (2024). The clinical trials landscape in immunoglobulin light chain amyloidosis: a systematic review. Blood Advances. 8(13). 3464–3467.

Cliff, Edward R. Scheffer, Hira Mian, Samer Al Hadidi, et al.. (2024). Evaluating early intervention in smoldering myeloma clinical trials: a systematic review. The Oncologist. 30(2). 2 indexed citations

Cliff, Edward R. Scheffer, Christopher M. Booth, Muhammad Aziz, et al.. (2024). Dietary interventions in cancer: a systematic review of all randomized controlled trials. JNCI Journal of the National Cancer Institute. 116(7). 1026–1034. 9 indexed citations

10.

Kesselheim, Aaron S., et al.. (2024). Confirmatory Trials of Accelerated Approval Drugs — Will Imposing Fines Reduce Delays?. New England Journal of Medicine. 391(14). 1273–1275. 4 indexed citations

11.

White, Joshua S., Rajshekhar Chakraborty, Luciano J. Costa, et al.. (2024). Multiple myeloma clinical trials exclude patients with the highest-risk disease: a systematic review of trial exclusion criteria. Leukemia & lymphoma. 65(14). 2163–2172. 1 indexed citations

12.

Reynolds, Gemma, Edward R. Scheffer Cliff, Benjamin W. Teh, et al.. (2024). Infections in patients with lymphoma treated with bispecific antibodies: a systematic review and meta-analysis. Blood Advances. 8(13). 3555–3559. 24 indexed citations

13.

Cliff, Edward R. Scheffer, et al.. (2023). Association of accelerated approval (AA) status with National Comprehensive Cancer Network (NCCN) guideline recommendation for cancer drug indications: A cross-sectional study.. Journal of Clinical Oncology. 41(16_suppl). 1599–1599. 1 indexed citations

14.

Lew, Thomas E., Edward R. Scheffer Cliff, Michael Dickinson, et al.. (2023). Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53 -mutated disease. Leukemia & lymphoma. 64(11). 1792–1800. 5 indexed citations

15.

Cliff, Edward R. Scheffer, Amar H. Kelkar, David A. Russler‐Germain, et al.. (2023). High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions. American Society of Clinical Oncology Educational Book. 43(43). e397912–e397912. 66 indexed citations

16.

Reynolds, Gemma, Edward R. Scheffer Cliff, Ghulam Rehman Mohyuddin, et al.. (2023). Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood Advances. 7(19). 5898–5903. 42 indexed citations

17.

Mohyuddin, Ghulam Rehman, Rajshekhar Chakraborty, & Edward R. Scheffer Cliff. (2023). The promise and harms of screening for plasma cell dyscrasias. British Journal of Haematology. 200(6). 704–707. 1 indexed citations

18.

Kelkar, Amar H., Edward R. Scheffer Cliff, Caron A. Jacobson, et al.. (2023). Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma. Annals of Internal Medicine. 176(12). 1625–1637. 18 indexed citations

19.

Chakraborty, Rajshekhar, Samer Al Hadidi, Edward R. Scheffer Cliff, & Ghulam Rehman Mohyuddin. (2023). Is aggressive treatment of smoldering myeloma the path to curing myeloma?. Blood Advances. 7(15). 3932–3935. 5 indexed citations

20.

Russler‐Germain, David A., Edward R. Scheffer Cliff, & Nancy L. Bartlett. (2023). Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis. Blood. 142(25). 2216–2219. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact